Drug intelligence / Profile preview

CNS10

Development stage: Phase 1
Lead developer: Cedars-Sinai
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraspinal, Intracortical, Subretinal, Striatal

Overview

CNS10 refers to a human neural progenitor cell line derived from stem cells. These cells are designed to differentiate primarily into astrocytes and are being investigated for their neuroprotective and neuronal support capabilities in various neurodegenerative diseases. The cell line can be genetically engineered, for example, to produce glial cell line-derived neurotrophic factor (GDNF), enhancing its therapeutic potential by promoting the survival of neuronal cells.

Other names: human neural progenitor cellsneural progenitor cells

Beyond the preview

Go deeper on CNS10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CNS10.